Ankylosing Spondylitis

You have full text access to this OnlineOpen article

Development and validation of a case ascertainment tool for ankylosing spondylitis

  1. Michael H. Weisman1,¶,*,
  2. Lan Chen2,
  3. Daniel O. Clegg3,
  4. John C. Davis Jr.4,
  5. Robert W. Dubois5,
  6. Pamela E. Prete6,‖,
  7. Laurie M. Savage7,
  8. Laura Schafer8,††,
  9. Maria E. Suarez-Almazor9,‡‡,
  10. Hsing-Ting Yu5,
  11. John D. Reveille10

Article first published online: 28 DEC 2009

DOI: 10.1002/acr.20009

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 1, pages 19–27, 15 January 2010

Additional Information

How to Cite

Weisman, M. H., Chen, L., Clegg, D. O., Davis, J. C., Dubois, R. W., Prete, P. E., Savage, L. M., Schafer, L., Suarez-Almazor, M. E., Yu, H.-T. and Reveille, J. D. (2010), Development and validation of a case ascertainment tool for ankylosing spondylitis. Arthritis Care Res, 62: 19–27. doi: 10.1002/acr.20009

Author Information

  1. 1

    Cedars-Sinai Medical Center, Los Angeles, California

  2. 2

    Penn Presbyterian Medical Center, Philadelphia, Pennsylvania

  3. 3

    University of Utah, Salt Lake City

  4. 4

    University of California, San Francisco

  5. 5

    Cerner LifeSciences, Beverly Hills, California

  6. 6

    Veterans Administration Healthcare System, Long Beach, California

  7. 7

    Spondylitis Association of America, Sherman Oaks, California

  8. 8

    Seattle, Washington

  9. 9

    University of Texas MD Anderson Cancer Center, Houston

  10. 10

    University of Texas Health Science Center at Houston

  1. Dr. Weisman has received research grants from Abbott, Centocor, and Wyeth, and has received consultant fees from serving on the advisory/data safety monitoring board for Amgen/Wyeth.

  2. ‖

    Dr. Prete has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from UCB.

  3. ††

    Ms Schafer owns stock in Abbott Laboratories.

  4. ‡‡

    Dr. Suarez-Almazor has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from BMS, Genentech, and Roche.

*8700 Beverly Boulevard, Suite B-200, Los Angeles, CA 90048

Publication History

  1. Issue published online: 28 DEC 2009
  2. Article first published online: 28 DEC 2009
  3. Manuscript Accepted: 20 AUG 2009
  4. Manuscript Received: 23 MAR 2009

Funded by

  • Spondylitis Association of America
  • Centocor
  • Abbott
  • Amgen
  • Wyeth
  • Pfizer

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (152K)

REFERENCES

  • 1
    Walker BF. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord 2000; 13: 205–17.
  • 2
    Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008; 8: 8–20.
  • 3
    Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, and the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008; 58: 15–25.
    Direct Link:
  • 4
    Sieper J, Braun J. New treatment strategies in ankylosing spondylitis: proceedings of the Ankylosing Spondylitis Workshop; 2002 Jan 18–19; Berlin, Germany. Ann Rheum Dis 2002; 61 Suppl 3: iii1–2.
  • 5
    Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA–B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61–6.
  • 6
    Khan MA. Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 2002; 61 Suppl 3: iii3–7.
  • 7
    Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis: results of a 10-year followup. J Rheumatol 1988; 15: 1109–14.
  • 8
    Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, et al. Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002; 61 Suppl 3: iii51–60.
  • 9
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349–56.
  • 10
    Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755–65.
    Direct Link:
  • 11
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93.
  • 12
    Rudwaleit M, Sieper J. Infliximab for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2005; 5: 1095–109.
  • 13
    Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998; 56: 225–40.
  • 14
    Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63: 535–43.
  • 15
    Kellgren JH, Jeffrey MR, Ball L. The epidemiology of chronic rheumatism. Oxford (UK): Blackwell Scientific; 1963.
  • 16
    Bennett PH, Burch TA. Population studies of the rheumatic diseases. Amsterdam (The Netherlands): Excerpta Medica Foundation; 1968.
  • 17
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
  • 18
    Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Evaluation of early diagnostic criteria for ankylosing spondylitis in a 10 year follow-up. Z Rheumatol 1990; 49: 82–7.
  • 19
    Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis [abstract]. JAMA 1977; 237: 2613–4.
  • 20
    Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54: 569–78.
    Direct Link:
  • 21
    Goie The H, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985; 24: 242–9.
  • 22
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121–3.
  • 23
    Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006; 73: 285–95.
  • 24
    Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 Suppl 3: iii8–18.
  • 25
    Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 2005; 64: 659–63.
  • 26
    Borenstein DG. Chronic low back pain. Rheum Dis Clin North Am 1996; 22: 439–56.
  • 27
    Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001; 344: 363–70.
  • 28
    Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995; 34: 1074–7.
  • 29
    Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095–102.
  • 30
    Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005; 81: 207–12.
  • 31
    Olmos LI, Dakik H, Gordon R, Dunn JK, Verani MS, Quinones MA, et al. Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease. Circulation 1998; 98: 2679–86.
  • 32
    Akkoc N, Khan MA. Epidemiology of ankylosing spondylitis and related spondyloarthropathies. In: WeismanMH, ReveilleJD, van der HeijdeD, editors. Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby; 2006. p. 117–31.
View Full Article (HTML) Get PDF (152K)